Krister Barkovich

Affiliations: 
2013- Cellular and Molecular Pharmacology University of California, San Francisco, San Francisco, CA 
Google:
"Krister Barkovich"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Guiley KZ, Stevenson JW, Lou K, et al. (2019) p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science (New York, N.Y.). 366
Yueh C, Rettenmaier J, Xia B, et al. (2019) Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. Journal of Medicinal Chemistry
Ocasio CA, Warkentin AA, McIntyre PJ, et al. (2018) Type II kinase inhibitors targeting Cys-gatekeeper kinases display orthogonality with wild type and Ala/Gly-gatekeeper kinases. Acs Chemical Biology
Barkovich KJ, Moore MK, Hu Q, et al. (2018) Chemical genetic inhibition of DEAD-box proteins using covalent complementarity. Nucleic Acids Research
Zhang J, Yao TW, Hashizume R, et al. (2016) Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. Journal of Neuro-Oncology
Floor SN, Barkovich KJ, Condon KJ, et al. (2016) Analog sensitive chemical inhibition of the DEAD-box protein DDX3. Protein Science : a Publication of the Protein Society. 25: 638-49
Barkovich KJ, Hariono S, Garske AL, et al. (2012) Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discovery. 2: 450-7
Nicolaides TP, Li H, Solomon DA, et al. (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7595-604
Nicolaides TP, Barkovich K, Hariono S, et al. (2010) Abstract 1973: Targeting activated alleles of EGFR derived from glioma and lung cancer: Correlating kinase active-site occupancy with efficacy Cancer Research. 70: 1973-1973
See more...